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Abstract
Introduction: The large volume of diagnostic tests required
by the response to the COVID-19 pandemic resulted in a
shortage of commercial nasopharyngeal swabs. In an effort
to alleviate the shortage, swabs created by 3D printing may
be a solution.
Methods: We designed and produced 3D printed swabs and
sought to compare their ability to detect SARS-CoV-2 in patients admitted for COVID-19 or who were suspected of having COVID-19.
Results: A total of 30 patients were swabbed with a com-

Introduction
During the coronavirus-19 (COVID-19) pandemic, materials were in short supply including personal protective equipment (PPE), ventilators, viral transport
medium, and nasopharyngeal swabs. The shortages were compounded by the increased demand in
“hotspots” like New York and Louisiana. Creative
solutions were approved for PPE and viral transport
medium by the Centers for Disease Control and Prevention (CDC).[1] Emergency use authorizations were
granted by the Food & Drug Administration for ventilators and the analysis of alternative body fluids for the
diagnosis of COVID-19.[2] However, a nasopharyngeal
specimen remains the standard diagnostic method for
COVID-19, especially in asymptomatic patients.
Working to alleviate the need for an increased demand of nasopharyngeal swabs, and using 3D technology available to make models for dental implants
out of resin, we designed and created a 3D printed
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mercial and a 3D printed swab. Results matched in 27 of 30
patients (90%). Two patients were discordant with a positive
commercial swab and a negative 3D printed swab and another was discordant because the 3D printed swab was positive and the commercial swab was negative. The sensitivity
was 89%, specificity was 92% and Cohen’s kappa coefficient
was 0.80.
Conclusion: The 3D printed swabs performed acceptably
compared to the commercial swab and may be considered
for use in lieu of a commercial swab.

swab resembling a commercial flocked nasopharyngeal swab. Certain physical and handling parameters
were included in the design, but it was unknown if
it would actually extract SARS-CoV-2 from a mucus
membrane of someone’s nasopharynx and elute the
virus into the transport media so that it could be detected by reverse transcription-polymerase chain reaction (RT-PCR) analysis. If a manufacturer does not
specify a certain swab to be used with their kit, then a
new swab should have in-house validation first.[3] The
objective of this study was to compare the detectability
of SARS-CoV-2 from the nasopharynx of a commercial
swab to our novel 3D printed swab.

Methods
Setting and Population
This was a cohort prospective study of non-consecutive
patients and healthcare workers with a recent diagnosis
of, or suspicion for, COVID-19. (IRB # 20.0334) It was
1
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Figure 1. The comparison of design of a commercially available, flocked, nasopharyngeal swab (above) to a 3D-printed one (below).

performed at two acute care hospitals of UofL Health
(an affiliate of the University of Louisville School of
Medicine) and required Institutional Review Board approved informed consent. There was a recently implemented policy at the time of the study that was
relevant; all patients admitted to the hospital were
screened upon admission. Recently identified COVID19 positive populations, or those who tested negative but who had signs or symptoms consistent with
COVID-19, were candidates for enrollment.
Sample collection
A commercial swab and a 3D printed swab were inserted into the nasopharynx of each subject in succession during the same encounter per standard methods
(insertion for 10 seconds with some rotation) and then
inserted into a viral transport media tube with a sealed
cap for transport to the laboratory on campus. The laboratory was CLIA certified under an emergency use
authorization by the FDA and had been used to perform approximately 4,500 samples prior to initiating
the present study. Internal validation of the laboratory
had been performed with the established CLIA certified University of Louisville Infectious Diseases Research Laboratory. A goal of testing 30 COVID-19 positive people was established per standard recommendations for validation with at least 90% agreement.[4]
Data Collection and Management
All data for this study were de-identified and kept in a
REDCap database. Demographic information was col-
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lected for each patient. The primary information collected was the result of each swab used in each subject. If a subject had been previously positive, then the
time from the previous test to the present test was also
recorded.
3D Printed Swab Design and Production
Guidance for the swab design for 3D printing was provided by an on-line research collective that provided
insight in to testing and evaluation of different swab
designs and materials.[5] A design similar to a typical commercial swab was chosen (Figure 1). Clinicians
required that the material be flexible so it would not
break off during use, that the collection end be comfortable for the patient and not cause any trauma to
the tissues, and that there be a notch between 80-100
mm from the tip in order to break the swab off into the
transport tube containing media. An open lattice design with a domed tip was selected (Figure 2). Test
swabs were produced from Envisiontec (Envisiontec,
Inc., Dearborn, MI) E1 guide soft material, and 3D
printed using direct light projection with a 3D printer
(NewPro3D, North Vancouver, BC). After the printing
phase, swabs were washed in 99% alcohol for 10 min,
washed again in new 99% isopropyl alcohol, dried for
30 minutes at 38º Celsius, and then cured with an UV
curing unit at 100% for 10 minutes. All swabs were
individually inspected, prepared for sterilization, and
subjected to internal testing for collection ability and
physical properties. UV-Vis spectroscopy was run to
ensure that the swab material did not affect the transport media. The commercially available FLOQSwab
2
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a)

b)

Figure 2. The tip of a) a nasopharyngeal commercial swab and b) a 3D-printed swab.

(COPAN Diagnostics, Brescia, Italy) was used as a reference swab for comparison to the 3D printed swabs.
Definitions
The CDC has defined that a positive result means that
two viral RNA targets (N1 and N2) were detected in the
sample.[6] The PCR cycle threshold (Ct) values were
set at 38; meaning below 38 was detected and above 38
was not detected. If neither target was detected, then
the result interpretation was negative. If only one target was detected, then the result was ‘inconclusive’ and
the test was run again from the same sample. An internal control to detect human DNA (RNaseP) was included to ensure cells were obtained from the swabbing procedure and to detect any sample inhibition. If
no human or viral fragments were identified, then the
result was deemed ‘invalid’ and the CDC recommends
recollecting another specimen. A recollection was not
performed for the present study and so if a sample was
invalid, the matched pair were excluded.
Statistics
Comparative proportional analyses were performed to
assess sensitivity, specificity, positive predictive value,
and negative predictive value. Because only two values may be compared with these tests—positive or
negative—and because indeterminate values were not
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positive, patients with two indeterminate tests were
considered negative. Additionally, Cohen’s Kappa
Statistic was used to measure agreement of diagnostic results between the 3D printed and commercial
swab groups.[7] Ct values for N1 and N2 were plotted
against each to produce paired plots.

Results
There were 32 total enrolled subjects in the study. Two
subjects had an invalid swab, so the matched pairs
were excluded leaving 30 patients. Demographic and
clinical information is included in Table 1. All subjects had already been diagnosed with COVID-19 except one who had tested negative despite bilateral infiltrates with a right pleural effusion, and who was ultimately diagnosed with metastatic cancer. The median
time from the admission surveillance swab to enrollment for all subjects was 2 days.
Results matched in 27 of 30 patients (90%). Among
the patients included, 15 matched as positive and 12
matched as negative. Two were discordant because the
commercial swabs were positive (considered true positives) and the 3D swabs were negative (considered false
negatives). Another one was discordant because the
commercial swab was negative (considered true negative) and the 3D swab was positive (considered false
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Table 1. Demographic and clinical information for patients diagnosed with or suspected for COVID-19 who were swabbed with a commercial
nasopharyngeal swab and a 3D printed swab.

Variable

Subjects (n=30)

Age (median [IQR])
Female (%)
History of pulmonary disease
COPD (%)
Asthma (%)
Other (%)
Days between Symptoms Starting and Admission (median [IQR])
Days between Admission and Study Swab (median [IQR])
ICU Required (%)
Ventilator Required (%)
Absolute Lymphocyte Count (mean±SD), cells/mL
Ferritin (median [IQR]), ng/mL
D-dimer (median [IQR]), µg/mL FEU

58 [46, 71]
17 (57)
4 (13)
4 (13)
4 (13)
1 [1, 3]
2 [2, 4]
16 (53)
15 (50)
1,220±1,050
16 [9, 24]
14 [6, 21]

Abbreviations: COPD, chronic obstructive pulmonary disease; ICU, intensive care unit;
IQR, interquartile range; SD, standard deviation.

positive). The sensitivity was 89%, specificity was 92%,
positive predictive value was 94% and the negative predictive value was 86%. Cohen’s kappa coefficient was
0.80.
For subjects whose swabs were either positive or who
had one swab test positive, the Ct values were plotted
against each other (Figure 3). For indeterminate pairs
with only one Ct value, the complement sample was
attributed the least positive value of 39. Values closer
to the identity line (45º one-to-one line) correspond to
more similarity between the swabs.

Discussion
The primary finding of this study was that the sensitivity and specificity were acceptable for the 3D printed
swab with respect to a commercial swab. Swabbing
patients and identifying virus requires a series of steps
performed in the present study including capturing the
virus from someone’s nasopharynx with a swab, transferring the swab to transport media, and identifying viral RNA targets using PCR analysis. All results are important, positive or negative, thus it is important to be
as accurate as possible. A false negative may result in
a patient being taken out of isolation and exposing others, while a false positive may, and likely would, result
in someone staying in quarantine or isolation inappropriately, and even going on to die alone.
When calculating sensitivity, an experiment (e.g., 3D
printed swab) is measured against a reference standard
(e.g., commercial swab). A commercial swab is certainly not 100% accurate as false negatives do occur.
In the present study, one discordant sample was positive with the 3D printed swab, but negative with the
commercial swab. This was labeled as a false positive
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3D printed swab result because the commercial swab
was the reference, but in actuality it was a true positive
result while the commercial swab was falsely negative
because it occurred in a patient who had tested positive prior to being enrolled and was being considered
positive clinically. Globally, false negative tests during the COVID-19 pandemic were ignored in patients
with consistent signs, symptoms and radiographical
evidence of COVID-19. False negative results may be
related to swab technique, transport or laboratory error.
The implication of the sensitivity and specificity generated with the present data are either to proceed with
mass production to fill the void created by the COVID19 pandemic or redesign a better 3D printed swab. At
this time, several thousand 3D printed swabs have been
created using our design for locally conducted COVID19 evaluation.
Nasopharyngeal swabs are considered a class I device,
which is not regulated by the FDA, but using a swab
that is not specified by a manufacturer to be used with
their kit is not recommended if it has not been shown
to be accurate. Our data were similar to another comparison study between a commercial nasopharyngeal
swab, a repurposed urogenital cleaning swab and four
printed 3D prototypes with Cohen’s kappa coefficients
ranging from 0.85 to 0.90.[8] There are other prototypes of printed 3D swabs being tested. Manufacturing companies (Carbon, Redwood City, CA; Formlabs,
Somerville, MA; Markforged, Watertown, MA;) currently manufacture and distribute 3D printed nasopharyngeal swabs for the purpose of detecting COVID-19,
but efficiency data were not provided.
Limitations of the study include the commercial swab
serving as a gold standard reference, which it is certainly not in actual practice. Potential reasons for discordant results may have been the variability of col4
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Figure 3. Scatterplot of cycle threshold values for a) N1 and b) N2 for all samples with at least one swab in a pair that was positive. For
discordant pairs, the swab without a Ct value was attributed a value of 39—the closest value to negative.

lection between samplings. Although swabbing once
should not preclude virus from being collected by a
subsequent swab, the depth that a patient allows a
swab inserted does vary. Sometimes, swabs have blood
on them and in differing amounts, which may interfere with PCR analysis. The study was strengthened
by consistency in the swab printing process and consistency in swab inspection criteria after printing and before steam autoclave sterilization. It was also strengthened by matching swab technique, using similar viral
transport media and running pairs together in the same
batch for RT-PCR analysis.
Future studies may address testing a different swab de-

sign, a different body site (e.g., nasal versus nasopharyngeal) or a different body fluid (e.g., nasopharyngeal
versus saliva). Advantages of each would be higher
viral capture, more comfort and more convenience, respectively.
Conclusion
A 3D manufactured swab with locally designed specifications was found to have a sensitivity and specificity
of 89% and 92%, respectively. The 3D printed swab
tested may be considered appropriate for use independently now, but future optimization studies would be
beneficial.
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